The effects of treatment with IL-12 and/or Epo on MmB16 melanoma growth in B6D2F1 mice. Mice were inoculated with 1 × 106 melanoma cells into the footpad of the right hind limb and treated with the intratumoral injections (days 7 to 13, arrows) of IL-12 (0.1 μg/injection), Epo (20 U/injection; twice daily), or IL-12 in combination with Epo (the same doses). Tumor volume was determined as described previously.15 (A) A pilot study with four B6D2F1 mice per group. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls; ▴, IL-12 + Epo; ◊, IL-12; ▿, control. (B) Additional experiment with five to six B6D2F1 mice in each of the groups. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls and Epo-treated mice; ** P < .01: IL-12- and IL-12 + Epo–treated mice versus controls and Epo-treated mice (Student's t-test); ▴, IL-12 + Epo; ◊, IL-12; ▪, Epo; ▿, control.
